Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00370552 · ClinicalTrials.gov registry record · Phase 2
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
A Phase 2 study, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT00370552 is a Phase 2 study that has completed, run by R-Pharm. The registered enrollment target is 136 participants.
The verdict
NCT00370552, a Phase 2 study, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer. The study will also assess the safety of this combination treatment.
Interventions
- DRUG Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg
- DRUG Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg
- DRUG Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00370552
The ClinicalTrials.gov registry entry for NCT00370552 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is R-Pharm, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg is the first listed.
NCT00370552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00370552 about?
NCT00370552 is a clinical study titled "A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer". The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer. The study will also assess the safety of this combination treatment.
What is the current status of trial NCT00370552?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2007-03. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00370552?
The interventions under investigation include: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg (DRUG), Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg (DRUG), Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00370552?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.